To sum up, overexpression of EZH2 may drive NAFLD progression, and pharmacologic inhibition of EZH2 could be a promising strategy for treating NAFLD (Figure 2). The gene discussed is EZH2; the disease is metabolic dysfunction-associated steatotic liver disease.